Alterity Therapeutics Limited (ATH.AX)

0,0060 +0,0010 (+20,00%) Börsenschluss: 04:10PM AEST

Alterity Therapeutics Limited

350 Collins Street
Level 14
Melbourne, VIC 3000
Australia
61 3 9349 4906
https://alteritytherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 11

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Geoffrey Paul Kempler B.Sc.	Co-Founder & Non-Executive Chairman	313,3k	N/A	1955
Dr. David A. Stamler M.D.	Chief Executive Officer	925,95k	N/A	1961
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A.	CFO & Company Secretary	N/A	N/A	1959
Dr. Rudolph Emile Tanzi Ph.D.	Chief Scientific Advisor and Member of Research & Development Advisory Board	N/A	N/A	1959
Dr. Steven D. Targum	Chief Medical Advisor	N/A	N/A	N/A
Dr. Robert Cherny	Head of Research	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Corporate Governance

Alterity Therapeutics Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.